Article thumbnail

Switching to Aripiprazole as a Strategy for Weight Reduction: A Meta-Analysis in Patients Suffering from Schizophrenia

By Yoram Barak and Dov Aizenberg

Abstract

Weight gain is one of the major drawbacks associated with the pharmacological treatment of schizophrenia. Existing strategies for the prevention and treatment of obesity amongst these patients are disappointing. Switching the current antipsychotic to another that may favorably affect weight is not yet fully established in the psychiatric literature. This meta-analysis focused on switching to aripiprazole as it has a pharmacological and clinical profile that may result in an improved weight control. Nine publications from seven countries worldwide were analyzed. These encompassed 784 schizophrenia and schizoaffective patients, 473 (60%) men and 311 (40%) women, mean age 39.4 ± 7.0 years. The major significant finding was a mean weight reduction by −2.55 ± 1.5 kgs following the switch to aripiprazole (P < .001). Switching to an antipsychotic with a lower propensity to induce weight gain needs be explored as a strategy. Our analysis suggests aripiprazole as a candidate for such a treatment strategy

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2943136
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2008). A 12-month follow-up study of treating overweight schizophrenic patients
  2. (2009). A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder,”
  3. (2009). A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia,”
  4. (2008). A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine,”
  5. (2006). A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice:
  6. (2009). A review of the safety and tolerability of aripiprazole,”ExpertOpiniononDrugSafety,vol.8,no.3,pp.373–386,
  7. (2009). A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole,”
  8. (2005). Amantadine for weight gain associated with olanzapine treatment,”
  9. (2009). Aripiprazole versus other atypical antipsychotics for schizophrenia,” Cochrane Database of Systematic Reviews,n o .4 ,A r t i c l eI D CD006569,
  10. (2006). B.ChavezandR.A.Poveda,“Efficacywithhigh-dosearipiprazole after olanzapine-related metabolic disturbances,”
  11. (2010). Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study,”
  12. (2007). Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review,”
  13. (2006). Corey-Lisle et al., “Naturalistic impact of second-generation antipsychotics on weight gain,”
  14. (2003). D.E.Casey,W.H.Carson,A.R.Sahaetal.,“Switchingpatients to aripiprazole from other antipsychotic agents: a multicenter randomized study,”
  15. (2009). Effectiveness of switching to aripiprazole from atypical antipsychotics in patientswithschizophrenia,”ClinicalNeuropharmacology,vol.
  16. (2009). Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study,”
  17. (2007). Interventions to reduce weight gain in schizophrenia,”
  18. (2006). Metabolic findings from the CATIE trial and their relation to tolerability,”
  19. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study,”
  20. (2007). open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice
  21. (2003). P i g o t t ,W .H .C a r s o n ,A .R .S a h a ,A .F .T o r b e y n s
  22. (2006). Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report,”
  23. (2009). schizophrenia PORT psychopharmacological treatment recommendations and summary statements,”
  24. (2007). Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia,”
  25. (2009). Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder,”
  26. (1998). The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions,”
  27. (2009). The risks and benefits of switching antipsychotics: a case study approach,” Perspectives in Psychiatric Care,
  28. (2008). Uzc´ ategui et al., “Pharmacological management of atypical antipsychotic-induced weight gain,”